The first patient with small cell lung cancer has been dosed in a trial of peluntamig (PT217) combined with chemotherapy.
PrimeC has been given an ‘Orphan Drug’ status by the FDA (Food and Drug Administration) and EMA (European Medicines Agency).
February 28, 2025 (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, ...
As we observe Rare Disease Day today, let us take a look at seven drugs poised to be approved to address rare diseases in ...
RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and OS Therapies Inc. (NYSE American:OSTX) on the RedChip Small Stocks, Big Money™ show, a sponsored ...
The policy environment for rare disease and orphan medicines is complex and encompasses regulation, reimbursement, and ...
Hosted on MSN3d
Neurotech receives positive opinion for orphan status in Rett Syndrome from European drug regulatorNeurotech has received positive feedback from the European Medicines Agency (EMA) on its orphan drug application for NTI164 ...
TNG462 granted Orphan Drug Designation for treatment of pancreatic cancer –– Investigational New Drug (IND) application for TNG456, a ...
An independent Data Safety Monitoring Board (DSMB) for the Phase 3 DRAGON trial recommends trial continuation without any modifications, ...
Vir Biotechnology, Inc. ( NASDAQ: VIR) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback